Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer
Gastric cancer (GC) is the fifth most common malignant neoplasm in the world among all malignant tumors. Currently, the “gold” standard of treatment for patients with non‑metastatic cancer of the stomach and esophageal–gastric junction is surgical treatment, which is complemented by perioperative ch...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2023-06-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/920 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568621067403264 |
|---|---|
| author | M. V. Sedova M. A. Batov V. S. Tretyak A. A. Kolomeytseva V. M. Khomyakov N. N. Volchenko A. A. Fedenko A. D. Kaprin |
| author_facet | M. V. Sedova M. A. Batov V. S. Tretyak A. A. Kolomeytseva V. M. Khomyakov N. N. Volchenko A. A. Fedenko A. D. Kaprin |
| author_sort | M. V. Sedova |
| collection | DOAJ |
| description | Gastric cancer (GC) is the fifth most common malignant neoplasm in the world among all malignant tumors. Currently, the “gold” standard of treatment for patients with non‑metastatic cancer of the stomach and esophageal–gastric junction is surgical treatment, which is complemented by perioperative chemotherapy according to the FLOT scheme, which includes four courses of therapy before surgery and four after. However, according to statistics, less than half of patients complete all adjuvant courses of FLOT chemotherapy due to the high toxicity of the regimen and a decrease in the functional status of patients in the postoperative period. In this regard, studies are being conducted to study the tolerability of total neoadjuvant chemotherapy, when all courses are held at the preoperative stage in order to carry out all stages of treatment in full. International studies have shown the results of the use of targeted (ramucirumab, trastuzumab, pertuzumab), immune drugs (pembrolizumab, nivolumab, ipilimumab), S‑1 in combination with chemotherapy as part of the combined treatment of gastric and esophageal‑ gastric junction cancer. The emergence of new therapeutic agents previously studied in metastatic GC may change approaches to the treatment of localized and locally advanced GC.The review presents the features of perioperative therapy regimens in patients with resectable gastric and esophageal‑ gastric junction cancer in order to reduce the frequency of local and long‑term relapses and improve further prognosis. |
| format | Article |
| id | doaj-art-1dc044a732354a2bab18906bddce02c9 |
| institution | Kabale University |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2023-06-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-1dc044a732354a2bab18906bddce02c92025-02-03T00:57:40ZrusQUASAR, LLCИсследования и практика в медицине2410-18932023-06-0110210.17709/2410-1893-2023-10-2-8505Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancerM. V. Sedova0M. A. Batov1V. S. Tretyak2A. A. Kolomeytseva3V. M. Khomyakov4N. N. Volchenko5A. A. Fedenko6A. D. Kaprin7P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationFirst Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation; National Medical Research Radiological Centre, Ministry of Health of the Russian Federation; Peoples' Friendship University of Russia (RUDN University)Gastric cancer (GC) is the fifth most common malignant neoplasm in the world among all malignant tumors. Currently, the “gold” standard of treatment for patients with non‑metastatic cancer of the stomach and esophageal–gastric junction is surgical treatment, which is complemented by perioperative chemotherapy according to the FLOT scheme, which includes four courses of therapy before surgery and four after. However, according to statistics, less than half of patients complete all adjuvant courses of FLOT chemotherapy due to the high toxicity of the regimen and a decrease in the functional status of patients in the postoperative period. In this regard, studies are being conducted to study the tolerability of total neoadjuvant chemotherapy, when all courses are held at the preoperative stage in order to carry out all stages of treatment in full. International studies have shown the results of the use of targeted (ramucirumab, trastuzumab, pertuzumab), immune drugs (pembrolizumab, nivolumab, ipilimumab), S‑1 in combination with chemotherapy as part of the combined treatment of gastric and esophageal‑ gastric junction cancer. The emergence of new therapeutic agents previously studied in metastatic GC may change approaches to the treatment of localized and locally advanced GC.The review presents the features of perioperative therapy regimens in patients with resectable gastric and esophageal‑ gastric junction cancer in order to reduce the frequency of local and long‑term relapses and improve further prognosis.https://www.rpmj.ru/rpmj/article/view/920gastric cancerperioperative chemotherapyimmunotherapytarget therapy |
| spellingShingle | M. V. Sedova M. A. Batov V. S. Tretyak A. A. Kolomeytseva V. M. Khomyakov N. N. Volchenko A. A. Fedenko A. D. Kaprin Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer Исследования и практика в медицине gastric cancer perioperative chemotherapy immunotherapy target therapy |
| title | Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer |
| title_full | Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer |
| title_fullStr | Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer |
| title_full_unstemmed | Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer |
| title_short | Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer |
| title_sort | evolution of drug therapy in patients with resectable gastric and esophageal gastric junction cancer |
| topic | gastric cancer perioperative chemotherapy immunotherapy target therapy |
| url | https://www.rpmj.ru/rpmj/article/view/920 |
| work_keys_str_mv | AT mvsedova evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT mabatov evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT vstretyak evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT aakolomeytseva evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT vmkhomyakov evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT nnvolchenko evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT aafedenko evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer AT adkaprin evolutionofdrugtherapyinpatientswithresectablegastricandesophagealgastricjunctioncancer |